Toviaz
Product Images NDC 54868-6175

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Toviaz (NDC 54868-6175). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Physicians Total Care, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel (4 mg Tablet Bottle Label)

Label for Toviaz 4mg, showing distribution by Physicians Total Care, Inc. in Tulsa, OK. The label includes lot number 0000, expiration date 01/60, and a barcode with the number 61560300000. The manufacturer is noted as Schwarz Pharma Productions, located in Zwickau, Germany.*

FDA Label Image

Principal Display Panel (8 mg Tablet Bottle Label)

Label for Toviaz 8 mg tablets distributed by Physicians Total Care, Inc. It includes a lot number field (blank) and an expiration date (01/60). The label notes manufacturing by Schwarz Pharma Productions in Germany and shows a barcode with numeric code 61750300000.*

FDA Label Image

Chemical Structure (Toviaz 01)

Chemical structure diagram showing two molecular components associated with the product Toviaz. The first molecule features aromatic and ester groups with a nitrogen-containing side chain. The second molecule appears as a small organic acid structure. The image depicts the chemical structure of the active ingredient in Toviaz, as submitted by Physicians Total Care, Inc.*

FDA Label Image

Figure 1 (Toviaz 02)

A line graph titled 'Change in Number of Micturitions per 24 h (Study 1)' showing mean change from baseline in number of micturitions per 24 hours over 12 weeks. The x-axis represents weeks (0 to 12) and the y-axis represents mean change from baseline (-3.0 to 0.0). Three lines compare Placebo, Toviaz 4 mg, and Toviaz 8 mg groups. The Toviaz 8 mg group shows the greatest reduction in micturitions, followed by Toviaz 4 mg, with Placebo showing the least change.*

FDA Label Image

Figure 2 (Toviaz 03)

A line graph depicting changes in urge incontinence episodes per 24 hours over 12 weeks from baseline. It compares three groups: Placebo, Toviaz 4 mg, and Toviaz 8 mg. The y-axis shows the mean change in urge incontinence episodes, with all groups showing a decrease, while the x-axis represents weeks. Toviaz groups demonstrate a larger reduction than placebo.*

FDA Label Image

Figure 3 (Toviaz 04)

A line graph titled 'Change in Number of Micturitions per 24 h (Study 2)' showing mean change from baseline over 12 weeks. The x-axis represents time in weeks (0 to 12) and the y-axis represents mean change from baseline in number of micturitions per 24 hours, ranging from 0 to -3. Three lines illustrate results for Placebo (N=266), Toviaz 4mg (N=267), and Toviaz 8mg (N=267), with placebo showing a smaller decrease and both Toviaz doses showing a greater, sustained decrease over time.*

FDA Label Image

Figure 4 (Toviaz 05)

This chart depicts the change in urge incontinence episodes per 24 hours over 12 weeks in Study 2, comparing placebo, Toviaz 4 mg, and Toviaz 8 mg groups. The vertical axis shows mean change from baseline in episodes, while the horizontal axis shows weeks (0 to 12). The data points illustrate decreasing episodes with Toviaz treatment compared to placebo.*

FDA Label Image

Logo (Toviaz 06)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.